Professional Media briefs

Ascend Integrated Media announced the appointment of Darren Sextro to VP of sales. Sextro, who has worked in healthcare media since 2003, and B2B media since 1987, brings to the organization “a 20-plus year successful track record in media marketing, advertising sales, and both technical magazine and health care publication management,” according to Ascend president Barbara Kay.

Elsevier has acquired Spanish medical site Fisterra.com. The site provides access to Fisterrae, an e-clinical reference solution that integrates support resources for HCPs in a local language platform. The website's offerings currently include clinical guides and protocols, a clinical drug database with dosage calculators, a vaccination tool, electronic continuing medical education content and patient handouts, with a mobile app for patient point of care in development.

Quadrant HealthCom Inc. (QHI) has announced the promotion of Elizabeth Katz to publisher of Neurology Reviews. Katz has been with QHI for nearly four years, and most recently held the position of director of medical communications for the journal. Prior to joining QHI, Katz served as associate publisher for CNS Spectrums.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.